GlassScriptPhysician profile
James W Evans
NPI 1134384787
$13,123.97
in general payments reported to CMS, 2019-2025
78 companies · $1,989 in 2025
The $1,989 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,826 · 2020: $1,503 · 2021: $1,814 · 2022: $2,077 · 2023: $2,044 · 2024: $1,871 · 2025: $1,989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,804 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,803.96 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,753.88 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $940.84 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Merck Sharp & Dohme LLC | $889.76 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $866.72 | 2019-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $738.94 | 2019-2025 | |
| Amgen INC. | $514.88 | 2019-2023 | Lumakras, Kyprolis |
| Celgene Corporation | $462.11 | 2019-2025 | Reblozyl, Pomalyst |
| Genzyme Corporation | $413.31 | 2020-2025 | |
| Seagen INC. | $397.77 | 2019-2023 | Adcetris, Tukysa, Padcev |
| Eisai INC. | $388.38 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $369.51 | 2019-2023 | Imbruvica, Epkinly |
| Daiichi Sankyo INC. | $360.82 | 2019-2025 | Enhertu |
| Genentech USA, INC. | $300.89 | 2019-2025 | Venclexta, Polivy, Tecentriq |
| Janssen Biotech, INC. | $300.36 | 2019-2025 | Rybrevant, Tecvayli, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $287.84 | 2019-2025 |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.